For individuals of white European descent, certain variations of the gene HMGA1 are associated with type 2 diabetes mellitus, according to a study in the March 2 issue of JAMA.
Type 2 diabetes mellitus (DM) is a common metabolic disorder that affects nearly 250 million people worldwide, and is associated with major diabetes-related complications, including retinopathy, kidney disease and cardiovascular disease. Insulin resistance in muscle, liver, and fat tissue is a major feature of most patients with type 2 DM. There is considerable evidence that heredity is a major contributor to the insulin resistance of type 2 DM, according to background information in the article. "However, despite extensive investigations, including studies of candidate genes and the recent genome-wide association studies, the common genetic causes of insulin resistance remain elusive," the authors write. The researchers previously found that the protein HMGA1 is a key regulator of insulin receptor (INSR) gene expression.
Antonio Brunetti, M.D., Ph.D., of the University of Catanzaro, Catanzaro, Italy and colleagues conducted a study to examine the association of HMGA1 gene variants with type 2 DM, and included patients with type 2 DM and controls from 3 populations of white European ancestry. Italian patients with type 2 DM (n = 3,278) and 2 groups of controls (n = 3,328) were attending outpatient clinics and other health care sites in Calabria, Italy, during 2003-2009; U.S. patients with type 2 DM (n = 970) were recruited in Northern California clinics between 1994 and 2005 and controls (n = 958) were senior athletes without DM evaluated in 2004 and 2009; and French patients with type 2 DM (n = 354) and healthy controls (n = 50) were enrolled at the University of Reims in 1992. Genomic DNA was either directly sequenced or analyzed for specific HMGA1 mutations.
The researchers found that the most frequent functional HMGA1 variant, IVS5-13insC, was present in 7 percent to 8 percent of patients with type 2 DM in all 3 populations. The prevalence of this variant was higher among patients with type 2 DM (nearly 16 times higher odds of having this variant) than among controls in the Italian population (7.23 percent vs. 0.43 percent in one control group; and 7.23 percent vs. 3.32 percent in the other control group). In the U.S. population, the prevalence of IVS5-13insC variant was 7.7 percent among patients with type 2 DM vs. 4.7 percent among controls; in the French population, the prevalence of this variant was 7.6 percent among patients with type 2 DM and 0 percent among controls. In the Italian population, 3 other functional variants were observed. When all 4 variants were analyzed, HMGA1 defects were present in 9.8 percent of Italian patients with type 2 DM and 0.6 percent of controls.
"We believe our observation that nearly 10 percent of individuals with type 2 DM have deleterious variations in the gene encoding HMGAl has important clinical implications. First, the presence of these variants could serve as an early predictive marker of both insulin resistance and type 2 DM, especially in those individuals who have a family history of type 2 DM and related conditions. Second, the presence of these variants may predict the response to therapy. ... Third, individuals who have functional HMGA1 variants and type 2 DM may have a different clinical course than other patients with type 2 DM, including differences in the development of macrovascular and microvascular complications. Fourth, the search for new therapies for type 2 DM could include agents that upregulate the expression of HMGA1," the authors write.
"In conclusion, our results indicate that variants in the HMGA1 gene are associated with type 2 DM in individuals of white, European descent. Further studies of the HMGAl gene and its variants, including studies in other racial types, are needed to understand the role of HMGA1 in insulin resistance and type 2 DM."
(JAMA. 2011;305903-912. Available pre-embargo to the media at www.jamamedia.org)
Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Editorial: HMCA1, A Novel Locus for Type 2 Diabetes Mellitus
In an accompanying editorial, Abhimanyu Garg, M.D., of the University of Texas Southwestern Medical Center, Dallas, comments on the findings of this study.
"With the discovery of novel loci for type 2 DM and development of better understanding of the molecular mechanisms by which these variants affect the susceptibility of diabetes combined with the sophisticated metabolic phenotyping related to beta cell dysfunction, insulin resistance, incretin hormones, hepatic glucose, and lipid metabolism, distinct subtypes of type 2 DM will be recognized more clearly. This information may lead to targeted therapies for various subtypes of type 2 DM. ... It is anticipated that the discoveries of novel loci such as HMGA1 will soon be translated into therapeutic decision making, and thereby improve the health of patients with type 2 DM."
(JAMA. 2011;305938-939. Available pre-embargo to the media at www.jamamedia.org)
Editor's Note: Please see the article for additional information, including financial disclosures, funding and support, etc.
To contact Antonio Brunetti, M.D., Ph.D., email email@example.com. To contact editorial author Abhimanyu Garg, M.D., call Kristen Holland Shear at 214-648-3404 or email Kristen.firstname.lastname@example.org.
For More Information: Contact the JAMA/Archives Media Relations Department at 312-464-JAMA or email: email@example.com.